Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

In this study, researchers found a significant association between attention-deficit/hyperactivity disorder stimulant medications and alopecia universalis in children, although this finding was based on a small sample size.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.

In this update, researchers incorporated TGA-approved Janus Kinase inhibitors into the Australian treatment guidelines for chronic, moderate to severe Alopecia areata, aiming to enhance recommended therapies by providing guidance on the use and management of these systemic medications.

This review discusses recent advances in understanding the pathogenesis of autoimmune alopecia areata and reports no new clinical results; it highlights potential for developing more effective treatments.

This study constructed a model using serum levels of BMP2, CD8A, PRF1, and XCL1 as a non-invasive biomarker to accurately predict recurrence in patients with alopecia areata.

This case report describes the treatment of a 12-year-old female with Alopecia Areata using oral azathioprine.

This study identified at least eight genetic regions associated with alopecia areata, which may lead to the development of new targeted therapies based on these findings.

This case report reviews the identification and management of alopecia areata but does not provide new clinical findings.

This study found that individuals with alopecia areata experience variations in cortisol and insulin levels and adaptive mechanism pressures, which may serve as potential therapeutic targets.

This study identified four genetic loci on chromosomes 6, 10, 16, and 18 that may contribute to susceptibility for alopecia areata and suggested shared genetic factors with psoriasis.

This study found that pediatric alopecia areata patients with atopic predisposition showed heightened immune and inflammatory responses, including significant immune cell infiltration, compared to adults and healthy controls.

This Delphi study found that moderate-to-severe alopecia areata in Poland, Czechia, Russia, and Türkiye significantly impacts quality of life and highlights an unmet need for more effective treatments.

In this study, nail changes, particularly pitting, were associated with moderate to severe cases of alopecia areata and a positive family history, highlighting potential genetic factors in the condition.

This study supports the use of a national registry as an effective tool for documenting epidemiological data, disease progression, treatment responses, and quality of life impacts in patients with alopecia areata.

This study found that multidisciplinary group medical visits for patients with alopecia areata improved patient satisfaction, knowledge, and access to care at Lahey Hospital and Medical Center.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

Dupilumab may help treat alopecia areata, but more research is needed.

This study found a high prevalence of telogen effluvium among patients hospitalized for severe COVID-19, with most experiencing early onset and eventual complete hair regrowth.

In this study, the 308-nm excimer lamp was reported to be a safe alternative treatment for alopecia areata, with a 41.1% overall response rate and a 50% response rate in severe cases.

This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.

This source presents an expert consensus framework for determining which Australian patients with alopecia areata should receive subsidized JAK inhibitor therapy, emphasizing the need for future research including patient perspectives to enhance criteria, ensure fair treatment access, and evaluate real-world outcomes.

This review of real-world treatment options for AA indicates that current therapies are insufficient, with high dissatisfaction rates, highlighting a need for improved solutions.

This study reports that alopecia areata is a rare and typically cosmetic condition in horses, affecting breeds such as Appaloosas and quarter horses, with a possible seasonal pattern of worsening in spring and summer.

This study found that patients with alopecia areata have significantly higher medication adherence than those with atopic dermatitis, potentially due to the stability and controllability of alopecia areata symptoms.

The authors concluded that alopecia areata incognita, mainly affecting young females, generally has a more favorable prognosis than other types of alopecia areata.

This study highlights rapid advances in alopecia areata treatment following the identification of genetic variants associated with increased disease risk, suggesting potential for precision medicine approaches.

AGA patients have a lower quality of life than AA patients.

In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.